Key result
The use of angiotensin receptor-neprilysin inhibitors (ARNIs) in heart failure is associated with a reduction in NT-proBNP levels but an increase in BNP levels.
Why the study?
How should natriuretic peptide levels (NT-proBNP and BNP) be interpreted in heart failure patients treated with angiotensin receptor-neprilysin inhibitors (ARNIs)?
How should natriuretic peptide levels (NT-proBNP and BNP) be interpreted in heart failure patients treated with angiotensin receptor-neprilysin inhibitors (ARNIs)?
In patients with heart failure treated with ARNIs, NT-proBNP levels decrease while BNP levels increase, requiring careful interpretation of these biomarkers.
Answers are grounded in this paper and cite their sources.
Requires cautious BNP vs NT-proBNP interpretation in ARNI-treated HF; leaves open optimal thresholds for prospective validation.
Assessment of serum levels of natriuretic peptides, especially the amino-terminal portion (NT-proBNP) and the carboxy-terminal portion (BNP) of pro-B-type natriuretic peptide, has had a highly significant clinical impact on the diagnosis and prognostic stratification of patients with heart failure (HF). They are now an instrument with recognized value in this context and several studies have demonstrated their value in tailoring therapy for these patients. Following the recent advent of angiotensin receptor-neprilysin inhibitors (ARNIs), there is a need to review how these two biomarkers are interpreted in HF. The use of ARNIs is associated with a reduction in NT-proBNP but an increase in BNP levels. The authors of this concise article review the interpretation of natriuretic peptide levels in the light of the most recent evidence. A determinação dos níveis séricos de peptídeos natriuréticos (porção aminoterminal do peptídeo natriurético tipo B–NT-proBNP ou da porção carboxiterminal - BNP) constituiu avanço científico com impacto clínico muito relevante no diagnóstico e na determinação prognóstica de doentes com insuficiência cardíaca (IC). São hoje um instrumento com valor reconhecido nesse contexto e diversos estudos sugerem o seu interesse na titulação da terapêutica desses doentes. Recentemente, com o conhecimento do valor terapêutico do uso de inibidores da neprilisina/antagonista dos recetores da angiotensina, o uso desses dois biomarcadores na IC carece de interpretação diversa. O uso desses fármacos associa-se à redução dos níveis de NT-proBNP mas a aumento dos níveis de BNP. Os autores neste artigo conciso reveem a interpretação e valorização dos níveis de peptídios natriuréticos à luz da evidência mais recente.
No takes yet. Share an insight, caveat, or question.
Bettencourt et al. (2017) conducted a review in Heart failure. Angiotensin receptor-neprilysin inhibitors (ARNIs) was evaluated. The use of angiotensin receptor-neprilysin inhibitors (ARNIs) in heart failure is associated with a reduction in NT-proBNP levels but an increase in BNP levels.
Synapse has enriched 10 related papers. Consider them for comparative context: